Among adolescents and young adults, cTnI levels remain within normal ranges after mRNA-1273 vaccination, with no evidence of increased myocardial injury.
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
A virologist’s criticism of former NIH leaders Fauci and Collins fuels renewed scrutiny on Capitol Hill over COVID-19 origins ...
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the ...
Exclusive: Reform candidate David Booth is listed as the author of a paper arguing the pandemic was "staged" by Western ...
Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the ...
Morning Overview on MSN
Nanoparticle therapy targets lung tumors and cancer-related muscle loss
A team at Oregon State University has engineered lipid nanoparticles that deliver messenger RNA to lung tumors while ...
Now, the work has been awarded the prestigious Breakthrough Prize at the "Oscars of Science." Today, Jean Bennett, MD, PHD, and Albert Maguire, MD, both emeritus professors of Ophthalmology in the ...
Penn Medicine scientists blend AI and ingenuity to transform mRNA gene editing and personalized therapies redefining modern ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results